Viatris and Idorsia Forge Major Global R&D Alliance to Enhance Innovative Drug Portfolio

    Expands Viatris' Portfolio of Innovative Assets by Immediately Adding Two Phase 3 Assets, Selato...

February 28, 2024 | Wednesday | News
Boehringer Ingelheim plans to expedite the development of survodutide for MASH treatment

In a significant breakthrough for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), Boehringer Ingelheim's latest Phase II clinical...

February 26, 2024 | Monday | News
Sanofi's Rilzabrutinib Shows Promise in Phase 2 Trials for Chronic Spontaneous Urticaria

Sanofi-Aventis Groupe announced promising results from its Phase 2 RILECSU study, showcasing rilzabrutinib's ability to significantly reduce itch severity ...

February 26, 2024 | Monday | News
LabVantage Introduces a Digitally Native Ecosystem to Boost Speed and Success in R&D Laboratories

LabVantage Solutions, Inc., the premier provider of laboratory informatics solutions and services, has launched an integrated, digitally native ecosystem t...

February 22, 2024 | Thursday | News
Aleta Biotherapeutics and Cancer Research UK Launch ALETA-001 Phase 1/2 Trial for Relapsed B-Cell Malignancies

Aleta Biotherapeutics (Aleta), a pioneer in immuno-oncology with a focus on CAR T-Cell Engager (CTE) platforms, in collaboration with Cancer Research UK&rs...

February 21, 2024 | Wednesday | News
Tevogen Bio Launches Genetic Predisposition Study for Long COVID Treatment Advancements

Tevogen Bio Holdings Inc. ('Tevogen Bio') (Nasdaq: TVGN) announces its strategic initiative to advance research into Long COVID treatment, unveiling plans ...

February 21, 2024 | Wednesday | News
Biocytogen Pharmaceuticals Announces Antibody Evaluation and Option Agreement with Gilead Sciences

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315)  announces an antibody evaluation and option agreement with Gil...

February 20, 2024 | Tuesday | News
Vidac Pharma's VDA-1275 Shows Promising Efficacy Across Solid Tumor Models and Enhances Standard Treatments

Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN:GB00BM9XQ619; WKN: A3DTUQ), a pioneering oncology biopharmaceutical company, has revealed prom...

February 19, 2024 | Monday | News
Cytiva and LevitasBio Forge Path to Enhanced Single-Cell Analysis with Groundbreaking Collaboration

The amalgamation of Cytiva's pioneering technologies with LevitasBio's cutting-edge solutions seeks to streamline single-cell workflows, offering invaluabl...

February 12, 2024 | Monday | News
Biocon Biologics and Sandoz Australia Forge Partnership for Biosimilars Trastuzumab and Bevacizumab

Biocon Biologics Ltd (BBL), a leading biosimilars company and subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), has announced a significant five-ye...

February 09, 2024 | Friday | News
Celerion Attains CLIA Certification, Boosting Bioanalytical Lab Capabilities

  Celerion’s long-standing CLIA-certified and CAP-accredited clinical laboratories, including its Lincoln site, have paved the way for this ach...

February 07, 2024 | Wednesday | News
Novartis Bolsters Oncology Portfolio with MorphoSys AG Acquisition for EUR 2.7 Billion

The acquisition encompasses key assets such as pelabresib, a promising late-stage BET inhibitor for myelofibrosis (MF), and tulmimetostat, an early-stage i...

February 06, 2024 | Tuesday | News
Twist Bioscience Expands Express Genes Rapid Synthesis Service

The Express Genes offering, initially launched in November 2023, now extends to larger midiprep (10μg to 100 μg) and maxiprep (100μg to 1mg) DNA p...

February 05, 2024 | Monday | News
Qubit Pharma, Institut Curie, and University of Bordeaux Collaborate on Innovative Cancer Therapies

The three partners are joining forces to develop drug candidates that modulate the immune response of cancer patients and block the development of metast...

January 30, 2024 | Tuesday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close